These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 2144364)

  • 1. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Raycroft L; Wu HY; Lozano G
    Science; 1990 Aug; 249(4972):1049-51. PubMed ID: 2144364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of a potent transcription activating sequence in the p53 protein.
    Fields S; Jang SK
    Science; 1990 Aug; 249(4972):1046-9. PubMed ID: 2144363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles.
    Munroe DG; Peacock JW; Benchimol S
    Mol Cell Biol; 1990 Jul; 10(7):3307-13. PubMed ID: 1694008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of p53 mutants for transcriptional activity.
    Raycroft L; Schmidt JR; Yoas K; Hao MM; Lozano G
    Mol Cell Biol; 1991 Dec; 11(12):6067-74. PubMed ID: 1944276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type p53 can inhibit oncogene-mediated focus formation.
    Eliyahu D; Michalovitz D; Eliyahu S; Pinhasi-Kimhi O; Oren M
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8763-7. PubMed ID: 2530586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1.
    Bosselut R; Duvall JF; Gégonne A; Bailly M; Hémar A; Brady J; Ghysdael J
    EMBO J; 1990 Oct; 9(10):3137-44. PubMed ID: 2209540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line.
    Romano JW; Ehrhart JC; Duthu A; Kim CM; Appella E; May P
    Oncogene; 1989 Dec; 4(12):1483-8. PubMed ID: 2531855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional and post-transcriptional regulation of c-myc, c-myb, and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO.
    Klinken SP; Holmes KL; Morse HC; Thorgeirsson SS
    Exp Cell Res; 1988 Oct; 178(2):185-98. PubMed ID: 2458948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
    Hinds P; Finlay C; Levine AJ
    J Virol; 1989 Feb; 63(2):739-46. PubMed ID: 2642977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins.
    Dang CV; Lee WM
    J Biol Chem; 1989 Oct; 264(30):18019-23. PubMed ID: 2553699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53: oncogene or anti-oncogene?
    Lane DP; Benchimol S
    Genes Dev; 1990 Jan; 4(1):1-8. PubMed ID: 2137806
    [No Abstract]   [Full Text] [Related]  

  • 13. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
    Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
    Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of the serine 312 phosphorylation site does not alter the ability of mouse p53 to inhibit simian virus 40 DNA replication in vivo.
    Meek DW; Eckhart W
    J Virol; 1990 Apr; 64(4):1734-44. PubMed ID: 2157055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
    Finlay CA
    Mol Cell Biol; 1993 Jan; 13(1):301-6. PubMed ID: 8417333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transactivation of the p53 oncogene by E1a gene products.
    Braithwaite A; Nelson C; Skulimowski A; McGovern J; Pigott D; Jenkins J
    Virology; 1990 Aug; 177(2):595-605. PubMed ID: 2142558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of an isolated fos promoter element with AP-1 site homology reveals cell type-specific transcriptional properties.
    Velcich A; Ziff EB
    Mol Cell Biol; 1990 Dec; 10(12):6273-82. PubMed ID: 2147223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
    Hoppe-Seyler F; Butz K
    J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
    Zinszner H; Albalat R; Ron D
    Genes Dev; 1994 Nov; 8(21):2513-26. PubMed ID: 7958914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.